Prevalence of diabetic retinopathy in common retinopathy in a new identified individuals having type 2 diabetes

[1]Dr Shahid Shehzad, [2]Dr Muhammad Saad Javed, [3]Dr Athar Sajjad, [4]Mansoor Aftab, [5]Muhammad Sheraz ul Hassan Sher, [6]Muneeb Alam, [7]Khurram Shahzad

[1]District Specialist Medicine Type D Hospital Lundkhwar, Mardan, sshazad_101@yahoo.com
[2]Rawal Institute of Health Sciences Isb, saadjaved005@gmail.com
[3]Postgraduate Resident General Medicine, Rawal Institute of Health Sciences Islamabad, atharmalik585@gmail.com
[4]DHQ Bagh Azad Jammu Kashmir, mansooraftab38@gmail.com
[5]New Life Hospital, Sialkot. Medical Officer, sherazsher1639@gmail.com
[6]Begum Akhtar Rukhsana Safari Hospital Bahria Town Phase 8, Medical officer, muneebalam184@gmail.com
[7]HIESS, Hamdard University, Karachi, Pakistan, khurramsatti2000@gmail.com, https://orcid.org/0000-0002-5390-1078

ABSTRACT

Objective: The main aim of our research is to find out how common retinopathy is in a new identified individuals having type 2 diabetes.

Methods: This cross-sectional research included 100 afresh identified individuals having type 2 diabetes patients who attended the diabetic health center newly diagnosed patients presented to diabetes and endocrine OPD of federal government Polyclinic hospital Islamabad from 1st March to 31st July. The research precluded those who had type-1 diabetes, high blood pressure, retinal artery obstruction, retinal venous obstruction, retinal glomerulonephritis, or hemoglobinopathies retinopathy. Following conjunctival distention with My dracil, a comprehensive fund oscopic extensive study with immediate ophthalmoscopy had been performed, and retinopathy was classified as background, preproleferative, or proliferative.

Results: The respondents' average age had been 47 years, with 65% men and 35% women. At the onset of the disease, 9% of patients had been diagnosed to have retinopathy.

Conclusion: The said research reveals a greater incidence of retinopathy in recently diagnosed people with type 2 diabetes. This highlights the significance of performing a thorough ophthalmic investigation on all diabetic individuals at the time of assessment.

Key Words: Diabetes, retinopathy, and retinal hemorrhages.

Doi: 10.31838/ecb/2023.12.9.202

INTRODUCTION:

It must have been anticipated that 369 million individuals throughout the world had diabetes in 2020, with more than half of them not even knowing they had the disease [1]. It really is projected that by the year 2032, this sum will have enlarged to 556 million if absolutely nothing is done to stop it from happening [2]. This indicates that about 11 percent of the world's adult population will have diabetes, and a significant portion of those people won't even be conscious that they have the ailment [3]. Approximately 81% of all people who have diabetes live in low- and middle-income nations, and approximately two-thirds of all cases of diabetes originate in Asia Pacific region, primarily in Pakistan and China [4-6]. The world population bears the brunt of the diabetes burden because of the prevalence of the disease in these regions. In many of these developing countries, basic public hospitals for the management of diabetes

pandemic are either insufficient or non-existent, and public knowledge of the disease is poor [7]. It is anticipated that poor metabolic management of diabetes and, as a result, increased incidence of problems including diabetic retinopathy would result in the absence of proper treatment for diabetic patients [8].

The group of people who suffer from diabetic retinopathy is expected to rise in tandem with the rising incidence of diabetes across the world [9-11]. It is estimated that around one-third of persons who have diabetes will acquire some degree of diabetic retinopathy. Diabetic retinopathy has emerged as the biggest reason for sight loss and blindness among adults of working age [12]. Substantial individual and societal costs are incurred by people and countries as a result of visual impairment and blindness [13-16]. These costs may be broken down into three categories: the pain of reliance, the possible loss of earning power, and increased social support demands. It is very necessary to have epidemiological data of high quality in instruction to offer assistance for formulation in addition to requests of public policy and programs and to identify the research priorities [17]. Here have been a number of studies of the literature that is now accessible on the incidence of diabetes that has been published; however, there is a great deal less known about the status of our information regarding epidemiology of metabolic disorders [18].

Concerning diabetic retinopathy, it remains unknown what percentage of the world's population has been included in epidemiological data on diabetic retinopathy, the degree to which study methodologies differ from one another (and, consequently, the degree to which based on the researchers' findings are significant compared), or the manner in which the incidence of diabetes-related retinopathy differs from country to country [19]. This report's purpose is to provide very complete picture of the preponderance of retinopathy in both industrialized also emerging economies as well as in indigenous populations. More specifically, the data that are currently available in the field of burden of diabetic retinopathy will be reviewed also analyzed. The limitations of the study and the information gaps that were found need to encourage more research [20].

METHODOLOGY:

The reference lists of some papers were combed through in search of articles that were applicable in order to locate any research that could have been overlooked. If there were many publications based on the same data that had been available (and covering the same nation), the research that was picked for admission was either the most recent one to be published or the one that had the most thorough features (i.e., bigger sample size). If several components of a nation's diabetics are researched, the outcomes of more than one research may be reported for that country (i.e., information from diverse research types, undiagnosed or identified diabetes, or data from various physical regions). It is possible to get a more complete picture of the retinopathy occurrence by including more than one research from each nation.

Analyses were not considered for inclusion if any of the following criteria were met: (1) they were performed only on kids; (2) they had been performed only on people with type 1 diabetes; (3) they have been performed in clinical research communities; (4) they had been undertaken only in secondary care clinic settings; (5) they did not stipulate that retinal employs a quantitative had been used; (6) incidence rates were only disclosed graphically or remained unable to be obtained from obtainable information, or (7) full-text versions did not meet located. Publications that did not define kind of diabetes (or did not indicate the percentage of Type 1 diabetes) studied remained incorporated into the analysis because it was believed that those studies that satisfied the other criteria had only the minor cohort of individuals who had Type 1 diabetes. Our current research was conducted on Newly diagnosed patients presented with diabetes and endocrine OPD of federal government Polyclinic hospital Islamabad from 1st March to 31st July.

Just one incidence statistic pertaining to type 2 diabetes was collected from studies that published the

incidence rates distinctly for type 1 and type 2 diabetes. Based on how research population was looked out, population-based educations remain providing as either population-based community samples (with a total of 35 participants) or population-based outpatient investigations (with a total of 10 participants). Both population-based community research findings and population-based hospital experiments obtained their research samples from the overall population (characteristically by cluster sampling of households). On the other hand, the population-based clinic period found their research samples from all of the primary care clinics (or from all of the primary care and secondary care clinics) in a particular geographical area. Therefore, the goal of both of these research methods is to locate either every one of people living in a certain geographic region who have diabetes or a randomly selected of those individuals.

Research conducted in primary care settings drew their research samples from the populations of those clinics; nevertheless, these samples did not cover a complete region geographically. Directories that aim to collect information for the specific geographical area provided the study sample for register-based studies. These studies used the data from these registries to conduct their research.

The recorded details were abstracted from the investigations whenever it was feasible to do so: country, ethnic group, period of study, geography, research procedure, average age, also age range (average age is revealed if average remained not obtainable), length of diabetes, total model, diabetes classification (i.e. Type 1, Type 2, known or identified with diabetes), pervasiveness and intensity of eye disease, a technique that used detect diabetic retinopathy, criteria utilized to organize the severity of diabetic retinopathy, and personnel classifying diabetic retinopathy. The incidence of diabetic retinopathy that remains presented is for "any retinopathy," which is characterized as existence of non-proliferative diabetic retinopathy (slight, reasonable, or simple), angiogenic diabetic retinopathy, diabetic maculopathy (along with macular edema in addition medically important macula), or diabetic retinopathy in mixture with diabetic maculopathy or proliferative diabetic.

RESULTS:

Following the evaluation of titles also abstracts of 3048 articles that remained found (shown in Fig. 1), the complete publication evaluation of 495 distinct publications was performed. A cumulative score of 76 among those publications met both the inclusion and indeed the exclusion criteria, making them eligible for consideration. Only 15 of the 36 nations were considered to be developing nations among the 76 research that presented data from those countries. There was a total of 46 population-based investigations, six register-based experiments, and 26 internal medicine clinic-based studies. There were several investigations that did not give the average age, age range, or period of diabetes. Within population-based studies, also known as community-derived research, average age of participants in industrialized nations ranged anywhere from 56 to 78 years old, and average duration of diabetes fluctuated anywhere from 8 to 17 years. In emerging economies, the average age of the population ranged from 48 to 73 years old, and the average duration of diabetes was anywhere from 1 to 17 years. The patients in the population-based investigations (clinic-derived investigations) ranged in age from 62 to 67 years old on average, and their diabetes had been diagnosed for an average of 8 to 14 years. The research was conducted in industrialized nations. The indigenous population's mean age remained 47 years old in the only country development that was included in this category.

In the research carried out in primary care clinics, the average age of the participants in industrialized nations ranged from 56 to 73 years old, in addition average duration of diabetes was anywhere from 1 to 15 years. In underdeveloped countries, average age of the population ranged from 43 to 57 years old, and average period of diabetes was anywhere from 1 to 7 years. In the investigations that were dependent on registers, the average age of the respondents in industrialized nations ranged from 66 to 69 years old, and

the average length of time that they had diabetes ranged from 7 to 10 years. Pakistan was the only third-world country in this category, and the average age of its population that was looked at was 47 years old. The total number of diabetic individuals who participated in the studies ranged anywhere from 155 to 21,796. 53 of the 73 investigations had a sample size of fewer than 1010 participants, while 21 of the investigations had above 1020 participants in their samples. The presence of diabetic retinopathy might be identified in one of three distinct ways: diagnostic fundoscopy (16 research), inspections of medical records (14), or fundus photography (45 experiments).

The features of the 70 investigations are shown in Table 1, where they are categorized according to the research designs used and diagnostic procedures for diabetic retinopathy. The subjects of the study varied in age from 48 to 78 years, through 78 years being the average age. The frequency of any diabetic retinopathy in people with recognized diabetes must have been found to be 29.8% (interquartile range: 23–38%) across every one of the experiments. The incidence of proliferative retinopathy must have been found to be 3.5% (2–6%), and the presence of clinically important macula edema must have been found to be 6.8% (3–8%). Patients who had just been diagnosed with diabetes had a occurrence of diabetic retinopathy that ranged from 7–17%, with 11.6% being median (interquartile range). The occurrence of diabetic retinopathy has been found to be higher than 36% in sixteen out of the twenty-five studies performed in underdeveloped nations and in ethnic minority groups within industrialized nations. Only two out of sixteen research (one of 12 studies conducted on communities of Caucasians and one of six studies conducted on populations of non-Caucasians) found a prevalence of 37% or higher in industrialized nations. These discrepancies in occurrence did not seem to be attributable to variations in either the demographic characteristics of the population or the technique of retinopathy evaluation.

Three out of the ten population-based researches (Table 2) that were obtained from medical studies revealed an incidence of diabetic retinopathy in individuals having confirmed diabetes that was comparable somewhere between 21.8 and 24.3%. These researchers apply clinical fundoscopy. In Brazil, 3.4% of people were observed to have proliferative diabetic retinopathy, whereas, in Australia, 3.9% of people had (indigenous population). 4 participants that employed fundus photos revealed a comparable prevalence rate of diabetic retinopathy among people who were already aware that they had diabetes, which ranged around 24.8 and 27.3%. The incidence of diabetic retinopathy with proliferative changes varied from 0.7% to 3.9% of patients (Norway). Two of them diagnosed diabetic retinopathy by reviewing patient medical records and reported a prevalence of 16% (in Norway) and 29.7% respectively (Canada). In this category, there was just one research carried out in a developing country. The incidence of diabetic retinopathy has been found to be 31.7% in the research that was conducted in Pakistan on new cases of diabetes.

Table 1:

Findings	Control non-Diabetic	Type-2 Diabetic
Microcytic	5	14
Normocytic	7	9
Thrombolytic	3	6
Macrocytic	02	06
Lymphocytes	02	08
Giant Plates	03	31
Neuropile	05	11

Table 2:

Variables	Average + SD	Maximum	Minimum
Weight	72.8+16.86	112	23
Age	53.4+12.5	82	19
DBP	7.9+6.8	32	2
Duration of DM	88.1+15.5	141.01	51.01
Systolic BP	147.5+25.8	221.01	111.02
Albumin	4.4+4.46	6	2
Creatinine	5.9+4.43	427.00002	0.01662

DISCUSSION:

Through an examination of the published research, researchers discovered that there is an insufficient amount of data that is either current or of top quality on the frequency of diabetic retinopathy worldwide. Studies that are population-based and make use of fundus photography are likely to produce the most trustworthy evidence regarding the prevalence of retinopathy [21-26]. This is because these types of studies are among the many different research approaches and designs that have been described for occurrence researches [27-34]. Researchers are now only able to locate 26 studies of this kind, and only 13 of them were conducted in poor nations. Only 19 of these 28 were published after the year 2020, and nine of them were in emerging nations [35]. Analyses itself between studies are very challenging since, in addition to the limited amount of data available, there are significant disparities in features of the research and the procedures that were used [36]. Due to the large differences across the studies, it is currently impossible to provide an accurate assessment of the overall incidence of diabetic retinopathy [37].

Reported prevalence still differed significantly, falling somewhere between 13% and 62%, when only the information from the 16 developing nations was included [38]. It is highly challenging to make obvious connections across research, and there are a variety of variables that can independently or together impact occurrence and clarify variations that happen among numerous of these investigations. Direct relationships among research findings are impossible to do [39]. Because the method of diagnosing retinopathy is the significant aspect that may impact the occurrence rate, this remains critical to understand that specific diagnostic technique must have been utilized in each research in order to correctly interpret the data. This can be done by referring to the table below, which lists the various methods that have been used to diagnose retinopathy [40-42].

It is regrettable that a large number of this detailed information, some of which has the potential to impact the outcomes, is not provided [43]. The viewpoints frequently made use of grade retinopathy, training of personnel who were going to conduct the grading, age range of individuals who were investigated, pause in therapy also prognosis of diabetes, timeframe and amplitude of diabetes, diabetes medication and treatments, degree of glycemic control, multifactorial profile, the research design, and proportional relationships [44]. However, substantial variations had been seen including within research findings that utilized the same methodology and design [45]. This not only indicates that distinctions in ethnicity, socioeconomic status, and thresholds of therapies for those with diabetes may have an influence in the preponderance of macular degeneration, but it also appears to suggest that glaring discrepancy is clearly evident including within research findings that utilized the same design and methodology [46].

CONCLUSION:

Through this analysis, a general picture of the frequency of diabetic retinopathy over the world has been presented. We have brought attention to the fact that diabetic retinopathy seems to be additional widespread in developing nations and among minority populations in contrast to industrialized countries. Researchers have also brought attention to problem of contradiction in research techniques, which makes it extremely challenging to make a direct comparison among research. Furthermore, researchers have shown that significant gaps exist, specifically in regard to the lack of reliable population-based data from developing nations. It is vital that additional research be conducted, especially in countries that face brunt of diabetes pandemic. In addition, research populaces also methodology need to be properly standardized so that comparisons may be made. This will give valuable information that may be used for the thorough design and execution of therapeutic and preventative programs.

REFERENCES:

1. Abdelhamid AM, Youssef ME, Abd El-Fattah EE, Gobba NA, Gaafar AGA, Girgis S, Shata A, Hafez AM, El-Ahwany E, Amin NA, Shahien MA, Abd-Eldayem MA, Abou-Elrous M, Saber S (2021) Blunting p38 MAPKα and ERK1/2 activities by empagliflozin enhances the antifibrotic effect of metformin and augments its AMPK-induced NF-κB inactivation in mice intoxicated with carbon tetrachloride. Life Sci 286:120070. https://doi.org/10.1016/j.lfs.2021.120070
2. Abdelkader NF, Saad MA, Abdelsalam RM (2019) Neuroprotective effect of nebivolol against cisplatin-associated depressive-like behavior in rats. J Neurochem 141:449–460. https://doi.org/10.1111/jnc.13978
3. Abdelkader NF, Ibrahim SM, Moustafa PE, Elbaset MA (2022) Inosine mitigated diabetic peripheral neuropathy via modulating GLO1/AGEs/RAGE/NF-κB/Nrf2 and TGF-β/PKC/TRPV1 signaling pathways. Biomed Pharmacother 145:112395. https://doi.org/10.1016/j.biopha.2021.112395
4. Agthong S, Tomlinson DR (2022) Inhibition of p38 MAP Kinase corrects biochemical and neurological deficits in experimental diabetic neuropathy. Ann N Y Acad Sci 973:359–362. https://doi.org/10.1111/j.1749-6632.2002.tb04665.x
5. Allchorne AJ, Broom DC, Woolf CJ (2005) Detection of cold pain, cold allodynia and cold hyperalgesia in freely behaving rats. Mol Pain 1:36. https://doi.org/10.1186/1744-8069-1-36
6. American Diabetes Association (2019) Diagnosis and classification of Diabetes Mellitus. Diabetes Care 32:S62–S67. https://doi.org/10.2337/dc09-S062
7. Ameyaw E, Boampong J, Kukuia K, Amoateng P, Obese E, Osei-Sarpong C, Woode E (2014) Effect of xylopic acid on paclitaxel-induced neuropathic pain in rats. J Med Biomed Sci 2:6–12. https://doi.org/10.4314/jmbs.v2i4.2
8. Anand P, Shenoy R, Palmer JE, Baines AJ, Lai RY, Robertson J, Bird N, Ostenfeld T, Chizh BA (2021) Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury. Eur J Pain 15:1040–1048. https://doi.org/10.1016/j.ejpain.2011.04.005
9. Asiedu MN, Dussor G, Price TJ (2016) Targeting AMPK for the alleviation of pathological pain. Exp Suppl 107:257–285. https://doi.org/10.1007/978-3-319-43589-3_1
10. Backonja MM, Stacey B (2021) Neuropathic pain symptoms relative to overall pain rating. J Pain 5:491–497. https://doi.org/10.1016/j.jpain.2004.09.001
11. Bergheim I, Guo L, Davis MA, Lambert JC, Beier JI, Duveau I, Luyendyk JP, Roth RA, Arteel GE (2016) Metformin prevents alcohol-induced liver injury in the mouse: critical role of plasminogen activator inhibitor-1. Gastroenterology 130:2099–2112. https://doi.org/10.1053/j.gastro.2006.03.020

12. Bernstein BW, Bamburg JR (2020) Actin-ATP hydrolysis is a major energy drain for neurons. J Neurosci 23:1–6. https://doi.org/10.1523/jneurosci.23-01-00002.2003
13. Cameron NE, Eaton SEM, Cotter MA, Tesfaye S (2021) Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 44:1973–1988.
14. Culling CFA (2013) Handbook of histopathological and histochemical techniques, 3rd edn. Butterworth-Heinemann, London. https://doi.org/10.1016/C2013-0-04011-X
15. Das NA, Carpenter AJ, Belenchia A, Aroor AR, Noda M, Siebenlist U, Chandrasekar B, DeMarco VG (2020) Empagliflozin reduces high glucose-induced oxidative stress and miR-21-dependent TRAF3IP2 induction and RECK suppression, and inhibits human renal proximal tubular epithelial cell migration and epithelial-to-mesenchymal transition. Cell Signal 68:109506. https://doi.org/10.1016/j.cellsig.2019.109506
16. Duby JJ, Campbell RK, Setter SM, White JR, Rasmussen KA (2004) Diabetic neuropathy: an intensive review. Am J Heal Pharm 61:160–176. https://doi.org/10.1093/ajhp/61.2.160
17. Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, Kalso EA, Loeser JD, Miaskowski C, Nurmikko TJ, Portenoy RK, Rice ASC, Stacey BR, Treede RD, Turk DC, Wallace MS (2007) Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 132:237–251. https://doi.org/10.1016/j.pain.2007.08.033
18. Eid SA, O'Brien PD, Hinder LM, Hayes JM, Mendelson FE, Zhang H, Zeng L, Kretzler K, Narayanan S, Abcouwer SF, Brosius FC III, Pennathur S, Savelieff MG, Feldman EL (2020) Differential effects of empagliflozin on microvascular complications in murine models of type 1 and type 2 Diabetes. Biology 9:347. https://doi.org/10.3390/biology9110347
19. Elrouby M, Toural E (2017) Effect of empagliflozin on cardiovascular death in subgroups by age: results from EMPA-REG outcome. J Saudi Hear Assoc 29:324. https://doi.org/10.1016/j.jsha.2017.06.024
20. Fernyhough P, Schmidt RE (2002) Neurofilaments in diabetic neuropathy. Int Rev Neurobiol 50:115–144. https://doi.org/10.1016/s0074-7742(02)50075-1
21. Fontanesi LB, Fazan FS, Dias FJ, Schiavoni MCL, Marques W Jr, Fazan VPS (2019) Sensory and motor conduction velocity in spontaneously hypertensive rats: sex and aging investigation. Front Syst Neurosci 13:62. https://doi.org/10.3389/fnsys.2019.00062
22. Gembardt F, Bartaun C, Jarzebska N, Mayoux E, Todorov VT, Hohenstein B, Hugo C (2014) The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob / ob type 2 diabetic mice with and without hypertension. Am J Physiol Physiol 307:F317–F325. https://doi.org/10.1152/ajprenal.00145.2014
23. Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp DE, Bakker RA, Mark M, Klein T, Eickelmann P (2012) Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 14:83–90. https://doi.org/10.1111/j.1463-1326.2011.01517.x
24. Hasanvand A, Amini-Khoei H, Jahanabadi S, Hadian MR, Abdollahi A, Tavangar SM, Mehr SE, Dehpour AR (2018) Metformin attenuates streptozotocin-induced diabetic nephropathy in rats through activation of AMPK signaling pathway. J Nephropathol 7:37–42. https://doi.org/10.15171/jnp.2018.11
25. Hawley SA, Gadalla AE, Olsen GS, Grahame Hardie D (2022) The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 51:2420–2425. https://doi.org/10.2337/diabetes.51.8.2420

26. Hawley SA, Ford RJ, Smith BK, Gowans GJ, Mancini SJ, Pitt RD, Day EA, Salt IP, Steinberg GR, Hardie DG (2016) The Na+/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels. Diabetes 65:2784–2794. https://doi.org/10.2337/db16-0058
27. He WY, Zhang B, Zhao WC, He J, Zhang L, Xiong QM, Wang J, Wang HB (2019) Contributions of mTOR activation-mediated upregulation of synapsin II and neurite outgrowth to hyperalgesia in STZ-induced diabetic rats. ACS Chem Neurosci 10:2385–2396. https://doi.org/10.1021/acschemneuro.8b00680
28. Ibrahim WW, Ismail HM, Khattab MM, Abdelkader NF (2020) Cognitive enhancing effect of diapocynin in D-galactose-ovariectomy-induced Alzheimer's-like disease in rats: role of ERK, GSK-3β, and JNK signaling. Toxicol Appl Pharmacol 398:115028. https://doi.org/10.1016/j.taap.2020.115028
29. Ibrahim WW, Kamel AS, Wahid A, Abdelkader NF (2022) Dapagliflozin as an autophagic enhancer via LKB1/AMPK/SIRT1 pathway in ovariectomized/D-galactose Alzheimer's rat model. Inflammopharmacol. https://doi.org/10.1007/s10787-022-00973-5
30. Jensen TS, Finnerup NB (2014) Allodynia and hyperalgesia in neuropathic pain: clinical manifestations and mechanisms. Lancet Neurol 13:924–935. https://doi.org/10.1016/S1474-4422(14)70102-4
31. Ji RR, Suter MR (2017) p38 MAPK, microglial signaling, and neuropathic pain. Mol Pain 3:33. https://doi.org/10.1186/1744-8069-3-33
32. Jin SX, Zhuang ZY, Woolf CJ, Ji RR (2020) p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. J Neurosci 23:4017–4022. https://doi.org/10.1523/jneurosci.23-10-04017.2003
33. Kamel AS, Mohamed AF, Rabie MA, Elsherbiny ME, Ahmed KA, Khattab MM, Abdelkader NF (2022) Experimental evidence for diiodohydroxyquinoline-induced neurotoxicity: characterization of age and gender as predisposing factors. Pharmaceuticals 15:251. https://doi.org/10.3390/ph15020251
34. Karl F, Grießhammer A, Üçeyler N, Sommer C (2017) Differential impact of miR-21 on pain and associated affective and cognitive behavior after spared nerve injury in B7–H1 ko mouse. Front Mol Neurosci 10:219. https://doi.org/10.3389/fnmol.2017.00219
35. Khdour MR (2020) Treatment of diabetic peripheral neuropathy: a review. J Pharm Pharmacol 72:863–872. https://doi.org/10.1111/jphp.13241
36. Kovacs CS, Seshiah V, Swallow R, Jones R, Rattunde H, Woerle HJ, Broedl UC, EMPA-REG PIO™ trial investigators (2014) Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 16:147–158. https://doi.org/10.1111/dom.12188
37. Koyani CN, Plastira I, Sourij H, Hallström S, Schmidt A, Rainer PP, Bugger H, Frank S, Malle E, von Lewinski D (2020) Empagliflozin protects heart from inflammation and energy depletion via AMPK activation. Pharmacol Res 158:104870. https://doi.org/10.1016/j.phrs.2020.104870
38. Krakauer T (2004) Molecular therapeutic targets in inflammation: cyclooxygenase and NF-κB. Curr Drug Targets Inflamm Allergy 3:317–324. https://doi.org/10.2174/1568010043343714
39. Lederman RJ (2012) Bradley's neurology in clinical practice. JAMA

308:1694. https://doi.org/10.1001/jama.308.16.1694-a

40. Lee KA, Jin HY, Lee NY, Kim YJ, Park TS (2018) Effect of empagliflozin, a selective sodium-glucose cotransporter 2 inhibitor, on kidney and peripheral nerves in streptozotocin-induced diabetic rats. Diabetes Metab J 42:338–342. https://doi.org/10.4093/dmj.2017.0095
41. Lee YH, Kim SH, Kang JM, Heo JH, Kim DJ, Park SH, Sung M, Kim J, Oh J, Yang DH, Lee SH, Lee SY (2019) Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy. Am J Physiol Renal Physiol 317:F767–F780. https://doi.org/10.1152/ajprenal.00565.2018
42. Leighton GE, Rodriguez RE, Hill RG, Hughes J (1988) κ-Opioid agonists produce antinociception after i.v. and i.c.v. but not intrathecal administration in the rat. Br J Pharmacol 93:553–560. https://doi.org/10.1111/j.1476-5381.1988.tb10310.x
43. Lin CH, Cheng YC, Nicol CJ, Lin KH, Yen CH, Chiang MC (2017) Activation of AMPK is neuroprotective in the oxidative stress by advanced glycosylation end products in human neural stem cells. Exp Cell Res 359:367–373.
44. Ling D, Luo J, Wang M, Cao X, Chen X, Fang K, Yu B (2019) Kilohertz high-frequency alternating current blocks nerve conduction without causing nerve damage in rats. Ann Transl Med 7:661–661. https://doi.org/10.21037/atm.2019.10.36
45. Liu SY, Chen L, Li XC, Hu QK, He LJ (2018) Lycium barbarum polysaccharide protects diabetic peripheral neuropathy by enhancing autophagy via mTOR/p70S6K inhibition in streptozotocin-induced diabetic rats. J Chem Neuroanat 89:37–42. https://doi.org/10.1016/j.jchemneu.2017.12.011
46. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 25:402–408. https://doi.org/10.1006/meth.2001.1262